Tseng, Ling-Ming

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 515

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 364

CIP2A is a target of bortezomib in human triple negative breast cancer cells

Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research

Ubiquitin and proteasome pathwaysBreast Cancer Treatment Studies

Cited by 122

Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells

Chang, C. J., Chiu, J. H., Tseng, L. M., Chang, C. H., Chien, T. M., Wu, C. W., & Lui, W. Y. (2006) · European Journal of Clinical Investigation

HER2/EGFR in Cancer ResearchGenomics, phytochemicals, and oxidative stress

Cited by 80

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells

Liu, C.-Y., Huang, T.-T., Chu, P.-Y., Huang, C.-T., Lee, C.-H., Wang, W.-L., Lau, K.-Y., Tsai, W.-C., Chao, T.-I., Su, J.-C., et al. (2017) · Experimental & Molecular Medicine

Protein Tyrosine PhosphatasesCytokine Signaling Pathways and Interactions

Cited by 40